Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer

NCT03254511 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Neoplasms

Interventions

DRUG: Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable
RADIATION: Radiotherapy
DRUG: Chemotherapeutic Combinations

Sponsor

Mashhad University of Medical Sciences